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This study cross-sectionally examines in the elderly population: (a) the association of type 2 diabetes 
with executive function (EF); (b) the effect of BMI on both type 2 diabetes and EF; (c) the association 
between glycaemia control and EF in type 2 diabetes. 6823 older individuals with overweight/obesity 
and metabolic syndrome participating in the PREDIMED-PLUS study, were assessed with a battery of 
cognitive tests and a medical interview. ANOVA showed a significantly worse performance on EF in type 
2 diabetes vs. non-diabetic individuals. Two complementary models were displayed: (1) in the whole 
sample, the presence of type 2 diabetes, depressive symptoms and BMI had a direct negative effect on 
EF, while apnoea had an indirect negative effect; (2) in the diabetes subsample, higher illness duration 
was associated with worse performance in EF. Participants with type 2 diabetes and HbA1c<53 mmol/
mol displayed better cognitive performance when compared to those with HbA1c≥53 mmol/mol. Our 
results provide a controlled comprehensive model that integrates relevant neuropsychological and 
physical variables in type 2 diabetes. The model suggests that, to improve treatment adherence and 
quality of life once diabetes has been diagnosed, cognitive decline prevention strategies need to be 
implemented while monitoring depressive symptoms, BMI and glycaemia control.
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Type 2 diabetes is caused by a combination of resistance to insulin action and an inadequate compensatory insu-
lin secretory response1. This is one of the most frequent diseases among the elderly individuals, with studies 
reporting a prevalence ranging from 19% to 33% in general population2,3. With global population ageing at signif-
icant pace and given the high prevalence of type 2 diabetes among the elderly, the negative effects of this chronic 
metabolic disease on health and cognitive functioning are of notable clinical interest.
With this regards, the main cognitive domains that have been related to type 2 diabetes are the following: atten-
tion, memory, processing speed and executive function (EF; i.e. working memory, cognitive flexibility, inhibitory 
control, etc.), as well as global cognitive functioning. When examining cognitive impairment in older individuals 
(>60 years), results confirmed that patients with type 2 diabetes in comparison with those without type 2 diabetes 
displayed higher impairment in global cognitive function, working memory and cognitive flexibility4,5. Similarly, 
when exploring other cohorts of elderly population (>65) with normal cognition, it was confirmed that type 2 dia-
betes participants obtained lower scores than non-diabetic patients in some cognitive domains such as attention, 
psychomotor function, information-processing speed and executive function, but they did not differ in memory6,7.
Different prospective studies have analyzed the association between the presence of type 2 diabetes and the 
risk of cognitive dysfunction. In older adults (42–89 years), results showed that women with type 2 diabetes had 
an increased risk of major cognitive decline in verbal fluency after 4 years when compared with non-diabetic 
women8. Similarly, other longitudinal studies concluded that older women (>65) with type 2 diabetes experi-
enced an accelerated cognitive decline in general functioning and other specific domains, including visual and 
working memory as well as verbal fluency5,9,10. In addition, research in old population exploring the duration of 
type 2 diabetes point towards an association between the duration of this metabolic disease and a poorer perfor-
mance in verbal memory and concept formation11 as well as in general cognition10. A longer duration of type 2 
diabetes together with an earlier onset, has also been reported to increase the risk of mild cognitive impairment 
development12.
The increasing number of individuals suffering from type 2 diabetes among older people during the last few 
decades might be due to inappropriate dietary habits and a sedentary lifestyle, which lead to overweight and 
obesity. An elevated BMI may cause insulin resistance and it is common in adults with type 2 diabetes13. Some 
findings show that both high BMI and obesity are associated with a worsened performance in measures associ-
ated with EF, working memory, short-term memory and verbal fluency14–16.
Finally, type 2 diabetes has been associated with cognitive dysfunction regardless of ethnicity and cultural fac-
tors17. Nevertheless, other aspects seem to be relevant when examining the negative effects of type 2 diabetes on 
cognitive performance. In this line, different studies report that gender8, low glycaemia control18,19 as well as the 
presence of depressive symptoms20 are associated with worse cognitive performance in type 2 diabetes individu-
als. It has also to be note that sleep disorders can have an impact on cognition, especially in older age population 
at higher risk of cognitive decline21.
In light of previous studies and in order to specify the association between the presence of type 2 diabetes and 
cognitive decline in older individuals (above 55 years of age) with overweight/obesity and metabolic syndrome, 
the objectives of this study are: (a) to explore the associations of type 2 diabetes with cognitive performance (i.e.: 
EF); (b) to evaluate the effect of BMI on type 2 diabetes and cognitive performance when controlling for other 
confounding variables (e.g.: depressive symptoms, sleep disorders, education, age and sex); (c) to explore the 
association between glycaemia control and cognitive function performance in individuals with type 2 diabetes.
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Methods
This is a cross-sectional analysis on baseline data within the frame of the PREDIMED-Plus study, a 6-year mul-
ticenter, randomized, parallel-group, primary prevention clinical trial conducted in Spain to assess the effect 
of an intensive weight loss intervention program based on an energy-restricted traditional Mediterranean diet, 
physical activity promotion and behavioural support (intervention group), compared to a usual care interven-
tion and energy-unrestricted Mediterranean diet recommendations (control group). A more detailed descrip-
tion of the PREDIMED-plus study and the study protocol is available at http://predimedplus.com/wp-content/
uploads/2016/07/Protocolo_PREDIMED_PLUS_eng_23112016_adl.pdf. This study was registered at the 
International Standard Randomized Controlled Trial (ISRCT; http://www.isrctn.com/ISRCTN89898870) with 
number 89898870. All participants were recruited and randomized from October 2013 to December 2017 across 
23 centres from different universities, hospitals and research institutes of Spain. Each of these centres recruited 
participants from several Primary Care Health Facilities belonging to the National Health System. The eligible 
participants were community-dwelling adults (aged between 55 and 75 years in case of men; and between 60 and 
75 years in women) with overweight/obesity (BMI between 27 and 40 kg/m2), who met at least three components 
of the metabolic syndrome according to the updated harmonized criteria of the International Diabetes Federation 
and the American Heart Association and National Heart, Lung and Blood Institute22. Specific PREDIMED-plus 
exclusion criteria can be found in the website http://predimedplus.com/en. Participants included in the current 
analysis provided data on cognitive performance and depressive symptoms, as well as detailed specification of BMI, 
physical conditions and sociodemographic data. Additionally, glucose and HbA1c concentrations were measured 
at the same time point of the mood and cognitive assessment. All participants provided written informed consent, 
and the study protocol and procedures were approved according to the ethical standards of the Declaration of 
Helsinki by the Research Ethics Committees from all the participating institutions (Supplementary Info 1).
Exclusion criteria for the present analysis were: (1) reported dementia (2) head trauma, learning disability 
or intellectual disabilities; (3) presence of depression or a lifetime mental disorder according to DSM-5. Finally, 
all the included participants presented glucose levels within the normal range during the neuropsychological 
assessment.
Instruments/measures. All participants completed a self-report questionnaire for exploring depres-
sive symptoms as well as a set of neuropsychological tests for assessing different cognitive domains that 
included attention, short term memory, verbal fluency, cognitive flexibility, visuospatial skills and working 
memory. Sociodemographic information was also collected by means of a self-reported questionnaire and a 
hetero-administered clinical interview assessing medical conditions (including current presence of type 2 diabe-
tes and years of duration since its onset, presence of apnoea, etc.).
Clinical and neuropsychological assessment. -The Beck Depression Inventory–II (BDI-II)23 is a 21-item 
self-report measure for assessing the severity of depressive symptoms in adults and adolescents (ages from 13 to 
80 years). The BDI-II reflects the diagnostic criteria for Major Depressive Disorder listed in the Diagnostic and 
Statistical Manual of Mental Disorders (4th ed.)24. Scores for each item range from 0 to 3; the total score is the sum 
of all responses. The Cronbach’s alpha in our sample shows a good internal consistency (α = 0.883).
The Trail Making Test (TMT)25 consists of 25 circles spread out over two sheets of paper (parts A and B). In the 
part A, participants are requested to connect consecutive numbers (1–2–3–4-…) in the correct order by drawing 
a line. In the part B, they have to connect consecutive numbers and letters in an alternating numeric and alpha-
betic sequence (1-A, 2-B, 3-C-…). Each part is scored according to the time spent to complete the task (lower 
score mean better performance). TMT is frequently used to assess executive function. More specifically, TMT-A 
is used for measuring attention, psychomotor speed and visuospatial skills; while, TMT-B is used for measuring 
divided attention, cognitive flexibility and interference.
The Verbal Fluency Test26 assess verbal ability and executive control. Participants need to retrieve words of 
their language by accessing their mental lexicon, but also focus on the task and avoid repetition that involves 
executive control processes. In the phonemic fluency task, participants are requested to produce as many words 
as possible that start with the letter P during 60 seconds. Participants were asked to avoid producing names of 
people or places and repetitions of the same word with a different suffix. Secondly, in the semantic fluency task, 
participants have to name as many different animals as they can without repeating them during 60 seconds. The 
total raw score for each of the tasks corresponds to the number of words the participant achieves to say.
The Digit Span (DS) test of the Wechsler Adult Intelligence Scale-III (Spanish version)27 is compound of 
two different subtests: DS Forward, considered as a test of attention and short-term memory capacity; and DS 
Backward recall, considered as a test of working memory capacity. The DS Forward recall requires participants to 
repeat orally a series of random single digits in the same order they heard them; the sequence of digits varies in 
length from three to nine. Contrary, in the DS Backward recall participants are asked to repeat a series of random 
single digits in reverse order; the sequence varies from two to eight. The performance on the DS can be reported by 
a direct score of the backward performance (ranging from 1 to 16) and the forward performance (ranging from 1 
to 14) and, by the span of immediate recall (backward span range from 1 to 8 and forward span range from 1 to 7).
Anthropometric and biochemical measurements. Weight and height were measured with light clothing and 
no shoes with calibrated scales and a wall-mounted stadiometer, respectively. BMI was calculated as weight 
in kilograms divided by the square of height in meters. Serum glucose levels were measured using standard 
enzymatic methods. HbA1c was measured by standard routine methods and glycaemia control was specified 
(HbA1c<53 mmol/mol [7%])1.
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Statistical analysis. Analyses were carried out with Stata15 for Windows. We used the study baseline data-
base generated in August 2017. The comparisons of the cognitive measures between participants with and with-
out type 2 diabetes was done with ANOVA procedures adjusted for the individuals’ sex, age, years of school 
attendance and presence of sleep apnoea syndrome. Cohen’s-d coefficients measured the effect size for the mean 
comparisons (low effect size was considered low for |d|> 0.2, moderate for |d|> 0.5 and large for |d|> 0.8)28. The 
Finner’s method, a procedure included into the Familywise error rate stepwise procedures which offers a more 
powerful test than the classical Bonferroni correction29, was used to control Type-I error due to multiple compar-
isons. The same method was used to explore the association between glycaemia control (HbA1c<53 mmol/mol 
[7%]) and cognitive function performance in the subsample of participants who presented type 2 diabetes.
The underlying mechanisms between BMI, type 2 diabetes and cognitive measures were examined with 
path-analysis modelling, a straightforward extension of multiple regression techniques that can be used for both 
confirmatory and exploratory modelling. The aim of this procedure is to estimate the magnitude and significance 
of hypothesized connections/relationships into a set of variables, and so they allow to theory testing and theory 
development30. The Path analysis used in this study was implemented through Structural Equation Modelling 
(SEM) with exploratory aims, with the advantage (compared to classical regression models) to allow the inclusion 
of multiple relationships among a set of variables, including mediational associations. The maximum-likelihood 
estimation method of parameter estimation was used and goodness-of-fit was evaluated using standard statistical 
measures31: the root mean square error of approximation (RMSEA), Bentler’s Comparative Fit Index (CFI), the 
Tucker-Lewis Index (TLI), and the standardized root mean square residual (SRMR). Adequate model fit was 
considered if the following criteria were met: RMSEA< 0.08, TLI> 0.9, CFI> 0.9 and SRMR< 0.1; the global pre-
dictive capacity of the model was measured by the coefficient of determination. Separate models were obtained 
for the whole sample (n = 6,825) and for the type 2 diabetes sub-sample (n = 1,860).
Results
The initial sample was constituted of 6865 participants. According to the exclusion criteria of this study, for the 
present analyses forty nine participants were excluded for presenting hypo or hyperglycaemia during the cogni-
tive assessment (≤60 mmol/l, hypoglycaemia; ≥150 mmol/l, hyperglycaemia). The final sample for the present 
analysis consisted of 6823 participants (mean age: 64.95 years; 48.6% females) distributed as follow: 4964 with 
no type 2 diabetes and 1859 with reported type 2 diabetes. At the moment of the assessment most of the patients 
with type 2 diabetes had presented this affection for more than 5 years (55.4%), some of them during 1 to 5 years 
(32.2%) and a 10.4% of them were only diagnosed during the last year (see the Supplementary Figure S1 for the 
flowchart graphic of the sample which is available as online supporting material).
Table 1 includes the descriptive data for the categorical variables (top of the table) and quantitative measures 
(bottom part of the table), for the whole sample and stratified by the sub-samples defined by the presence-absence 
of type 2 diabetes. No differences between groups were found for the origin or the civil status. However, the 
subsample who presented type 2 diabetes included a higher proportion of men, non-employed, with lower level 
studies, older age, a higher prevalence of sleep apnoea and depression symptomatology, higher BMI and higher 
concentrations of HbA1c and glucose.
Comparison of cognitive measures between participants with and without type 2 diabetes. Table 2 
includes the results obtained in the ANOVA procedures adjusted for sex, age, years of school attendance and 
presence of apnoea. Some significant results emerged comparing patients with and without type 2 diabetes: the 
presence of type 2 diabetes was associated with lower scores in the phonological and semantic verbal fluency, and 
to higher scores in the trail making test.
Table  3 includes the ANOVA procedures exploring the relationship between glycaemia control 
(HbA1c<53 mmol/mol [7%] versus HbA1c≥53 mmol/mol [7%]) and cognitive function performance in the 
subsample of participants who presented type 2 diabetes. Statistical differences emerged for the measures of 
phonological fluency and digit backward, achieving better functioning (higher means) the participants into the 
HbA1c<53 mmol/mol (7%) group.
SEM examining the association between BMI, type 2 diabetes and cognitive functioning. Figure 1 
shows the standardized coefficients of the SEM obtained for the whole sample (first panel, n = 6,823) and for the 
subsample with type 2 diabetes (n = 1,859). Both models included a latent variable (labelled cognitive) which was 
defined by the cognitive scores analyzed in this study (as high the score in this variable the better the neuropsy-
chological functioning). Goodness-of-fit was obtained for both models, as well as very good global predictive 
capacity. Supplementary Info S2 and S3 contain the complete results of the path-analyses, including the param-
eters estimating the direct, indirect and total effects. contain the complete results of the path-analyses, including 
the parameters estimating the direct, indirect and total effects.
In the whole sample, the presence of type 2 diabetes was predictive of worse cognitive functioning (direct 
negative effect); while the BMI directly contributed on the cognitive performance (as high the BMI as poor the 
cognitive performance). In the subsample with type 2 diabetes, the higher duration of this metabolic condition 
was predictive of a lower cognitive functioning (direct effect), while BMI did not contributed to (with direct or 
indirect effects) on the cognitive levels.
Regarding the remaining variables included in the SEM, for both models better cognitive functioning was 
directly related to male sex, younger age and higher education. The apnoea achieved indirect effects on the cogni-
tive performance only in the whole sample, through one path-way: the presence of apnoea was directly related to 
type 2 diabetes, which was also a predictor of poor cognitive execution. No direct effect between the presence of 
apnoea and cognitive performance emerged in any of the SEM.
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Total
(n = 6,823)
Type 2 diabetes = absent
(n = 4,964)
Type 2 diabetes = present
(n = 1,859)
 χ2 df pn (%) n (%) n (%)
Sex
   Male 3506 (51.4%) 2485 (50.1%) 1021 (54.9%) 12.78 1 0.001
   Female 3317 (48.6%) 2479 (49.9%) 838 (45.1%)
Origin
   Europe 6651 (97.5%) 4825 (97.2%) 1826 (98.2%) 6.95 5 0.256
   South-America 153 (2.2%) 124 (2.5%) 29 (1.6%)
   North-Africa 10 (0.1%) 7 (0.1%) 3 (0.2%)
   South-Sahara 6 (0.1%) 5 (0.1%) 1 (0.1%)
   Asian 2 (0.0%) 2 (0.0%) 0 (0.0%)
   Other 1 (0.0%) 1 (0.0%) 0 (0.0%)
Civil status
   Single 340 (5.0%) 257 (5.2%) 83 (4.5%)
   Married 5230 (76.7%) 3778 (76.1%) 1452 (78.1%) 5.99 5 0.308
   Widow 711 (10.4%) 529 (10.7%) 182 (9.8%)
   Divorced 386 (5.7%) 278 (5.6%) 108 (5.8%)
   Separated 154 (2.3%) 120 (2.4%) 34 (1.8%)
   Religious 2 (0.0%) 2 (0.0%) 0 (0.0%)
Education
   University (high) 896 (13.1%) 681 (13.7%) 215 (11.6%) 17.22 4 0.004
   University (grade) 613 (9.0%) 465 (9.4%) 148 (8.0%)
   Secondary 1968 (28.8%) 1449 (29.2%) 519 (27.9%)
   Primary or less 3346 (49.1%) 2369 (47.7%) 977 (42.6%)
Employment
   Employed 1412 (20.7%) 1085 (21.9%) 327 (17.6%) 19.27 7 0.013
   Total incapacity 110 (1.6%) 71 (1.4%) 39 (2.1%)
   Work at home 1009 (14.8%) 736 (14.8%) 273 (14.7%)
   Student 51 (0.7%) 36 (0.7%) 15 (0.8%)
   Retired 3800 (55.7%) 2723 (54.9%) 1077 (57.9%)
   Work leave (>3 months) 55 (0.8%) 37 (0.7%) 18 (1.0%)
   Unemployed (incomes) 253 (3.7%) 180 (3.6%) 73 (3.9%)
   Unemployed (no-incomes) 133 (1.9%) 96 (1.9%) 37 (2.0%)
Weight group
   Over-weight:BMI ⊂ (25–30] 1831 (26.8%) 1355 (27.3%) 476 (25.6%) 5.31 4 0.204
   Obesity I: BMI ⊂ (30–35] 3351 (49.1%) 2449 (49.3%) 902 (48.5%)
   Obesity II: BMI ⊂ (35–40] 1589 (23.3%) 1122 (22.6%) 467 (25.1%)
   Obesity III: BMI>40 52 (0.8%) 38 (0.8%) 14 (0.8%)
Presence of sleep apnoea
   No 5948 (87.2%) 4374 (88.1%) 1574 (84.7%) 14.36 1 0.001
   Yes 875 (12.8%) 590 (11.9%) 285 (15.3%)
Tobacco use (at current)
   No 5975 (87.6%) 4351 (87.7%) 1624 (87.4%) 0.11 1 0.745
   Yes 848 (12.4%) 613 (12.3%) 235 (12.6%)
Alcohol use
   No 1432 (21.0%) 1014 (20.4%) 418 (22.5%) 3.46 1 0.126
   Yes 5391 (79.0%) 3950 (79.6%) 1441 (77.5%)
Mean ± SD Mean ± SD Mean ± SD F df p
Age (years-old) 64.95 ± 4.91 64.88 ±4.93 65.15 ± 4.86 4.23 1;6,821 0.040
Education level (years) 11.37 ± 5.23 11.53 ± 5.24 10.96 5.19 16.34 1;6,821 <0.001
BMI (kg/m2) 32.56 ± 3.44 32.49 ± 3.42 32.73 3.50 6.04 1;6,821 0.017
Glycated hemoglobin A1c, in % 6.14 ± 2.25 5.87 ± 2.51 6.87 1.01 239.69 1;6,821 <0.001
Plasma glucose levels (mg/dl) 112.48 ± 26.10 103.50 ± 15.21 136.54 33.03 3112.5 1;6,821 <0.001
Depression (BDI raw total) 8.47 ± 7.42 8.20 ± 7.22 9.20 ± 7.88 24.58 1;6,821 <0.001
Table 1. Descriptive variables of the studied simple. Note. p-value includes Finner’s correction for multiple 
comparisons. SD, standard deviation.
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As a synthesis of the results of the study, Figure S2 (Supplementary Material) includes the scheme of the main 
direct and indirect effects on the cognitive construct analyzed in the study.
Discussion
The present study examined the effect of type 2 diabetes on cognitive performance specifically with EF tasks, in 
a large cohort of 6823 patients above 55 years of age. Additionally, the role that BMI, apnoea, age, sex, depressive 
symptoms and education play in these effects was also explored or controlled when appropriate. Mainly, results 
display worse cognitive functioning when participants present type 2 diabetes, with a larger effect on those who 
have a longer duration of this metabolic condition. Additionally, some other variables are also found to directly 
or indirectly worsen cognitive function among this population, namely BMI, sex, depressive symptoms and 
education.
Within the first analysis when comparing patients presenting type 2 diabetes with individuals without type 2 
diabetes and controlling for other co-related variables that could interfere with the cognitive assessment (i.e.: sex, 
age, education and apnoea), results show a significantly worse cognitive performance on EF when type 2 diabetes 
is present. Thus, the presence of type 2 diabetes in patients above 55 years of age seems to have a clear impact 
on cognitive function which would not be explained by the education, age, sex or the presence of apnoea. In the 
same line, previous studies have also reported that type 2 diabetes has a negative impact on cognitive function 
and physical health4–10,32,33; taken together, our results add some extra evidence to previous findings and point 
towards the need to target these neurocognitive domains once type 2 diabetes has been diagnosed and its treat-
ment protocol implemented. In an attempt to further explore the underlying mechanisms of the reported associ-
ation between type 2 diabetes and cognitive performance, the present study sought to step further, by exploring 
the association of glycated haemoglobin with the neuropsychological measures in the subsample with type 2 
diabetes. Previous studies have found that individuals with a weighted mean HbA1c less than 53 mmol/mol (7%) 
performed significantly better on tests of motor speed and psychomotor efficiency than those subjects whose time 
weighted mean HbAlc was greater34. In our study, individuals with type 2 diabetes and HbA1c<53 mmol/mol 
(7%) displayed better cognitive function when compared to those with HbA1c≥53 mmol/mol (7%), specifically 
on verbal fluency and working memory which highlights the importance of maintain good glycaemia control in 
this population which is already at risk of cognitive decline.
Type 2 diabetes = absent
(n = 4,964)
Type 2 diabetes = present
(n = 1,859)
MD F1;6817 p 95% CI (MD) |d|Mean SD Mean SD
Phonological verbal fluency of letter P: total 12.40 4.59 11.74 4.39 0.66 33.93 <0.001* 0.44 0.88 0.15
Semantic verbal fluency of animals: total 16.22 4.96 15.63 4.74 0.58 22.63 <0.001* 0.34 0.82 0.12
Trail Making Test: A, total time (seconds) 52.14 27.66 54.02 28.74 −1.88 7.00 0.016* −3.26 −0.49 0.07
Trail Making Test: B, total time (seconds) 123.78 63.84 130.70 69.63 −6.92 17.91 <0.001* −10.13 −3.72 0.10
Digit: forward score 8.81 2.46 8.80 2.49 0.02 0.07 0.798 −0.13 0.16 0.01
Digit: backwards core 5.16 2.27 5.20 2.14 −0.04 0.29 0.637 −0.16 0.09 0.02
Digit: forward Span 5.70 1.35 5.61 1.33 0.10 2.94 0.114 −0.01 0.21 0.07
Digit: backwards Span 3.81 1.25 3.72 1.19 0.09 3.24 0.115 −0.01 0.19 0.07
Table 2. Comparison of the cognitive assessment variables between patients with and without reported type 
2 diabetes. Note. SD, standard deviation; MD, mean difference; |d|, Cohen’s-d measuring effect size. *Bold: 
significant comparison (0.05 level, including Finner’s correction). All the results adjusted for sex, age, education 
and presence of apnoea.





MD F1;1615 p 95% CI (MD) |d|Mean SD Mean SD
Phonological verbal fluency of letter P: total 11.90 4.44 11.35 4.35 0.55 7.16 0.036* 0.15 0.95 0.12
Semantic verbal fluency of animals: total 15.68 4.71 15.38 4.84 0.30 1.82 0.269 −0.14 0.74 0.06
Trail Making Test: A, total time (seconds) 54.32 28.45 53.92 27.86 0.40 0.09 0.807 −2.20 3.00 0.01
Trail Making Test: B, total time (seconds) 129.88 69.78 132.51 68.98 −2.63 0.68 0.507 −8.90 3.64 0.04
Digit: forward score 8.76 2.48 8.54 2.41 0.22 2.50 0.244 −0.05 0.49 0.09
Digit: backwards core 5.20 2.25 4.87 1.93 0.33 8.13 0.035* 0.10 0.56 0.16
Digit: forward Span 5.68 1.39 5.52 1.29 0.16 2.72 0.244 −0.03 0.34 0.12
Digit: backwards Span 3.71 1.25 3.70 1.15 0.01 0.02 0.888 −0.15 0.18 0.01
HbA1c 6.23 0.44 7.84 0.83 −1.61 257.2 <0.001* −1.67 −1.55 2.42
Table 3. Comparison for type 2 diabetes patients with HbA1c higher and lower than 53 mmol/mol (7%). 
Note. SD, standard deviation; MD, mean difference; |d|, Cohen’s-d measuring effect size. *Bold: significant 
comparison (0.05 level, including Finner’s correction). All the results adjusted for sex, age, education and 
presence of apnea.
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Additionally, we sought to assess the associations of the presence of type 2 diabetes and its duration, cognitive 
performance and BMI in a model that also took into account other variables reported to be associated with cogni-
tive performance (i.e.: sex, mood, education and apnoea). As a result of this analysis, two complementary differ-
ent models were obtained. These two models provide relevant information about the interaction and contribution 
of the described variables to the cognitive performance of population suffering from type 2 diabetes, which can 
help improving the current understanding and treatment of this affection. Firstly, it is important to note that, as 
expected, type 2 diabetes and a higher duration of this metabolic condition was associated with worse cognitive 
performance. Consequently, it seems highly important to implement cognitive stimulation protocols within the 
treatment of type 2 diabetes that could help to reduce the progression of the cognitive decline once type 2 dia-
betes has been diagnosed. Secondly, a high BMI has previously been linked to specific cognitive impairments in 
different sample populations, especially in extreme weight conditions14–16,35. Our findings with the whole sample 
model give extra evidence on the negative impact of higher BMI on cognitive performance with this older age 
sample population. Additionally, higher BMI also negatively affects the participants’ mood in our sample. In turn, 
the lower mood in our sample is linked to poorer cognitive performance, which has also been reported in another 
study conducted with clinically depressed individuals36. Thus, health programs should give special emphasis in 
promoting weight loss within these individuals as well as strategies to monitor and improve mood when needed. 
On the contrary, in our older age sample with overweight/obesity, BMI differences are not significant enough to 
be robustly linked to the presence or duration of type 2 diabetes. However, BMI is described as a risk factor for the 
occurrence of type 2 diabetes in older age population37. Thus, the results observed regarding the influence of BMI 
on type 2 diabetes may most certainly only be circumscribed to our sample.
With regards to the presence of sleep disturbances/disorders and cognitive decline21, in our sample sleep 
apnoea (which unsurprisingly presents an association with higher BMI) is only linked to cognitive decline 
through its role in type 2 diabetes. Finally, it is also relevant that as reported in older adult populations a better 
cognitive function is directly related to males, younger age and higher education38,39.
The present study should be considered under some limitations. Firstly, the cross-sectional design does not 
imply causality. Also, given that our study participants are senior adults with a metabolic syndrome the present 
findings cannot be extrapolated to other population groups. However, it is one of the strengths of this study that it 
is conducted with a large sample of men and women and analyses are adjusted for potential confounding factors. 
Thus, although the results cannot be generalizable to other populations, they are representative of individuals 
Figure 1. SEM model for the presence of type 2 diabetes (first panel) and for the duration of type 2 diabetes 
(second panel). Note. Continuous line refers to significant coefficients (<0.05 level). Dash-line refers to non-
significant coefficients. Grey font: covariance parameter.
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over 55 years of age who suffer from a metabolic syndrome. Future studies should further explore the associations 
reported regarding the presence of type 2 diabetes, cognitive decline and BMI in different sample populations. 
Cognitive dysfunction is of particular importance because of its impact on quality of life. Future studies should 
test if an early intervention for improving cognitive deficits as well as depressive symptoms would help to reduce 
de cognitive decline and to improve the type 2 diabetes treatment adherences as well as self-care and quality of life.
To conclude, in this cross-sectional assessment type 2 diabetes (including illness duration), high BMI and 
lower mood was linked to poorer cognitive function in older individuals with overweight/obesity and metabolic 
syndrome. A good glycaemia control in type 2 diabetes was associated with a better cognitive performance. Our 
results provide a controlled comprehensive model that integrates different neuropsychological and physical varia-
bles that are relevant in type 2 diabetes. The model also suggests that, to improve treatment adherence and quality 
of life once type 2 diabetes has been diagnosed, cognitive decline prevention strategies need to be implemented 
while closely monitoring depressive symptoms, BMI and glycaemia control. However, the etiopathogenic factors 
associated with the reported associations are still unclear.
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